Literature DB >> 11146599

Preoperative shunts in thalamic tumours.

A Goel1.   

Abstract

Thirty one patients with thalamic glioma underwent a pre-tumour resection shunt surgery. The procedure was uneventful in 23 patients with relief from symptoms of increased intracranial pressure. Eight patients worsened after the procedure. The level of sensorium worsened from excessively drowsy state to unconsciousness in seven patients. Three patients developed hemiparesis, 4 developed paresis of extra-ocular muscles and altered pupillary reflexes, and 1 developed incontinence of urine and persistent vomiting. Alteration in the delicately balanced intracranial pressure and movements in the tumour and vital adjacent brain areas could be the probable cause of the worsening in the neurological state in these 8 patients. On the basis of these observations and on review of literature, it is postulated that the ventricular dilatation following an obstruction in the path of the cerebrospinal fluid flow by a tumour could be a natural defense phenomenon of the brain.

Entities:  

Mesh:

Year:  2000        PMID: 11146599

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  3 in total

1.  Medulloblastoma in childhood-King Edward Memorial hospital surgical experience and review: Comparative analysis of the case series of 365 patients.

Authors:  Dattatraya Muzumdar; Amit Deshpande; Ratnesh Kumar; Ankur Sharma; Naina Goel; Nitin Dange; Abhida Shah; Atul Goel
Journal:  J Pediatr Neurosci       Date:  2011-10

2.  Surgical resection of thalamic tumors in children: approaches and clinical results.

Authors:  Marc Baroncini; Matthieu Vinchon; Jean-François Minéo; Fabienne Pichon; Jean-Paul Francke; Patrick Dhellemmes
Journal:  Childs Nerv Syst       Date:  2007-03-17       Impact factor: 1.532

3.  Surgical resection of unilateral thalamic tumors in adults: approaches and outcomes.

Authors:  Lei Cao; Chuzhong Li; Yazhuo Zhang; Songbai Gui
Journal:  BMC Neurol       Date:  2015-11-07       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.